Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumorsYAMADA, Yasuhide; TAMURA, Tomohide; MCGOVREN, J. Patrick et al.Cancer chemotherapy and pharmacology. 2006, Vol 58, Num 2, pp 173-182, issn 0344-5704, 10 p.Article

Paradoxical effects of ethoxidine, a topoisomerase I inhibitor, in the cellular processes leading to angiogenesis on endothelial cellsCLERE, Nicolas; FAURE, Sébastien; HELESBEUX, Jean-Jacques et al.Carcinogenesis (New York. Print). 2011, Vol 32, Num 3, pp 286-295, issn 0143-3334, 10 p.Article

Topoisomerase 1 Inhibitors and Cancer TherapyMOUKHARSKAYA, Julia; VERSCHRAEGEN, Claire.Hematology/oncology clinics of North America. 2012, Vol 26, Num 3, issn 0889-8588, vii, 507-525 [20 p.]Article

Safety pharmacology of CKD-602, a novel anticancer agentEUN JOO KIM; RAE KYONG LEE; JEONG EUN SUH et al.Arzneimittel-Forschung. 2003, Vol 53, Num 4, pp 272-279, issn 0004-4172, 8 p.Article

Mechanism of hydrolysis of a novel indolocarbazole topoisomerase I inhibitorBRESLIN, David; SATO, Yuichi; KARKI, Shyam B et al.European journal of pharmaceutical sciences. 2010, Vol 39, Num 5, pp 291-297, issn 0928-0987, 7 p.Article

A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumorsHURWITZ, Herbert I; COHEN, Roger B; MCGOVREN, J. Patrick et al.Cancer chemotherapy and pharmacology. 2007, Vol 59, Num 1, pp 139-147, issn 0344-5704, 9 p.Article

Apoptotic effect of CKD-602 (Camtobell®) on oral squamous cell carcinoma cell linesOK, Yong-Ju; MYOUNG, Hoon; KIM, Young-Kyun et al.Oral oncology (1997). 2009, Vol 45, Num 3, pp 266-272, issn 1368-8375, 7 p.Article

Synthesis and biological evaluations of novel indenoisoquinolines as topoisomerase I inhibitorsXIAOYUN ZHANG; RUBING WANG; LI ZHAO et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 2, pp 1276-1281, issn 0960-894X, 6 p.Article

Old class but new dimethoxy analogue of benzimidazole: a bacterial topoisomerase I inhibitorBANSAL, Sandhya; TAWAR, Urmila; SINGH, Manish et al.International journal of antimicrobial agents (Print). 2010, Vol 35, Num 2, pp 186-190, issn 0924-8579, 5 p.Article

Development of a Validated Immunofluorescence Assay for yH2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor ActivityKINDERS, Robert J; HOLLINGSHEAD, Melinda; TOMASZEWSKI, Joseph et al.Clinical cancer research (Print). 2010, Vol 16, Num 22, pp 5447-5457, issn 1078-0432, 11 p.Article

Batracylin (NSC 320846), a dual inhibitor of DNA topoisomerases I and II induces histone γ-H2AX as a biomarker of DNA damageASHUTOSH RAO, V; AGAMA, Keli; HOLBECK, Susan et al.Cancer research (Baltimore). 2007, Vol 67, Num 20, pp 9971-9979, issn 0008-5472, 9 p.Article

XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancerYURKOVETSKIY, Alexander V; FRAM, Robert J.Advanced drug delivery reviews. 2009, Vol 61, Num 13, pp 1193-1202, issn 0169-409X, 10 p.Article

Irinotecan HCI, an anticancer topoisomerase I inhibitor, frequently induces ovarian failure in premenopausal and perimenopausal womenTANAKA, Tetsuji; UTSUNOMIYA, Tomoko; UTSUNOMIYA, Hirotoshi et al.Oncology reports. 2008, Vol 19, Num 5, pp 1123-1133, issn 1021-335X, 11 p.Article

Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemiaMINDERMAN, Hans; O'LOUGHLIN, Kieran L; SMITH, Patrick F et al.Cancer chemotherapy and pharmacology. 2006, Vol 57, Num 1, pp 73-83, issn 0344-5704, 11 p.Article

A novel method to load topotecan into liposomes driven by a transmembrane NH₄EDTA gradientYUEHUI YANG; YANLING MA; SHAONING WANG et al.European journal of pharmaceutics and biopharmaceutics. 2012, Vol 80, Num 2, pp 332-339, issn 0939-6411, 8 p.Article

Genz-644282, a Novel Non-Camptothecin Topoisomerase I Inhibitor for Cancer TreatmentKURTZBERG, Leslie S; ROTH, Stephanie; FEI WANG et al.Clinical cancer research (Print). 2011, Vol 17, Num 9, pp 2777-2787, issn 1078-0432, 11 p.Article

Pharmacogenetic Pathway Analysis of IrinotecanROSNER, G. L; PANETTA, J. C; INNOCENTI, F et al.Clinical pharmacology and therapeutics. 2008, Vol 84, Num 3, pp 393-402, issn 0009-9236, 10 p.Article

Potential Oral Delivery of 7-Ethyl-10-Hydroxy-Camptothecin (SN-38) using Poly (amidoamine) DendrimersKOLHATKAR, Rohit B; SWAAN, Peter; GHANDEHARI, Hamidreza et al.Pharmaceutical research. 2008, Vol 25, Num 7, pp 1723-1729, issn 0724-8741, 7 p.Article

Metabolic Pathways of the Camptothecin Analog AR-67HORN, Jamie; MILEWSKA, Marta; ARNOLD, Susanne M et al.Drug metabolism and disposition. 2011, Vol 39, Num 4, pp 683-692, issn 0090-9556, 10 p.Article

Irinotecan Pharmacogenetics : Influence of Pharmacodynamic GenesHOSKINS, Janelle M; MARCUELLO, Eugenio; ALTES, Albert et al.Clinical cancer research. 2008, Vol 14, Num 6, pp 1788-1796, issn 1078-0432, 9 p.Article

Liquid chromatography-tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776HOLLERAN, Julianne L; PARISE, Robert A; YELLOW-DUKE, Archibong E et al.Journal of pharmaceutical and biomedical analysis. 2010, Vol 52, Num 5, pp 714-720, issn 0731-7085, 7 p.Article

Renal Function as a Predictor of Irinotecan-induced NeutropeniaDE JONG, F. A; VAN DER BOL, J. M; MATHIJSSEN, R. H. J et al.Clinical pharmacology and therapeutics. 2008, Vol 84, Num 2, pp 254-262, issn 0009-9236, 9 p.Article

Clinical Determinants of Response to Irinotecan-Based Therapy Derived from Cell Line ModelsALLEN, Wendy L; COYLE, Vicky M; JOHNSTON, Patrick G et al.Clinical cancer research (Print). 2008, Vol 14, Num 20, pp 6647-6655, issn 1078-0432, 9 p.Article

Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer modelsHOCH, Ute; STASCHEN, Carl-Michael; JOHNSON, Randall K et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 6, pp 1125-1137, issn 0344-5704, 13 p.Article

Kibdelomycin A, a congener of kibdelomycin, derivatives and their antibacterial activitiesSINGH, SheoB; GOETZ, Michael A; DORSO, Karen et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 23, pp 7127-7130, issn 0960-894X, 4 p.Article